DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease.
暂无分享,去创建一个
D. Sanghera | M. Kamboh | C. Aston | D K Sanghera | C E Aston | N Saha | M I Kamboh | N. Saha | N. Saha
[1] A. Nikiforova,et al. Antioxidative activity of high density lipoproteins in vivo. , 1993, Atherosclerosis.
[2] C. Walker,et al. Absence of "A"-esterase activity in the serum of a patient with Tangier disease. , 1989, Clinical biochemistry.
[3] S. Ratnam,et al. Serum paraoxonase polymorphism in three populations of southeast Asia. , 1991, Human heredity.
[4] C. Walker,et al. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.
[5] C. Abbott,et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.
[6] M. Jauhiainen,et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. , 1996, The Journal of clinical investigation.
[7] M. Blatter,et al. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. , 1993, European journal of biochemistry.
[8] B. La Du,et al. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[9] O. Lockridge,et al. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. Motulsky,et al. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. , 1988, American journal of human genetics.
[11] B. L. Du,et al. Structural and functional diversity of paraoxonases , 1996, Nature Medicine.
[12] C. Mannhalter,et al. A rapid method for the isolation of genomic DNA from citrated whole blood. , 1991, The Biochemical journal.
[13] D. Adler,et al. The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.
[14] D. Sanghera,et al. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[15] G. Siest,et al. An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism. , 1986, Annales de biologie clinique.
[16] G. Kitto. Homologous enzymes and biochemical evolution. , 1969 .
[17] M. Keifer,et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.
[18] G. Charpentier,et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes , 1995, The Lancet.
[19] C. Walker,et al. Low A-esterase activity in serum of patients with fish-eye disease. , 1987, Clinical chemistry.
[20] D. Arveiler,et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. , 1996, Atherosclerosis.
[21] C. Furlong,et al. Apolipoprotein J is associated with paraoxonase in human plasma. , 1994, Biochemistry.
[22] P. Winocour,et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.
[23] S. Adkins,et al. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.
[24] T. Diepgen,et al. Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. , 1986, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.
[25] B. La Du,et al. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.
[26] W. G. Hill,et al. Estimation of linkage disequilibrium in randomly mating populations , 1974, Heredity.
[27] J. Berliner,et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.
[28] G. Zimmerman,et al. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. , 1992, Transactions of the Association of American Physicians.
[29] A. Marian,et al. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. , 1995, The Journal of clinical investigation.
[30] P. Froguel,et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.
[31] P. Edwards,et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.